Clinical Trial Search

Primary: Time in Month to Clinical Definite Multiple Sclerosis (CDMS) From Kaplan-Meier Estimates — 15.6; 17.0 Month

Primary: ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS…

Primary: The Occurrence of ≥ 3 New T2 Lesions With or Without Gd+ Enhancement or Clinical Exacerbation Through 12 Months. — 26; 18 Participants — p=0.929

Primary: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion — 657.85; 590.54 days — p=0.0005

Primary: Percentage of Relapse-free RMS Subjects — 66.3 percentage of subjects

Primary: The Time From Randomization to the First Demyelinating Event (Acute or Development of an Initial Symptom Resulting in a Progressive Clinical Course) — 89.69; 77.81 weeks

Primary: MRI Parameter- Percent Brain Volume Change for 2 Years — -0.862; -0.49 percent change per year

Primary: Number of Disease-free Patients — 5; 12 participants — p=0.0493

Primary: Incidence of Treatment-Emergent Adverse Events in Subjects by Measuring Measuring Changes in Vital Signs — 0; 0 Adverse Events

Primary: Core Treatment Period: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) — 14.3; 8.7; 9.0; 26.0 percent probability — p=0.0087

Primary: Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) — 0 percentage of participants

Primary: The Primary Outcome Measure is the Number of "Combined Active Lesions" (CAL) by Monthly MRI at the Conclusion of the Study. — 0.63; 0.58 Average number of lesions per…

Primary: Proportion of Research Cohort Subjects Referred Into a Clinical Trial or Offered Treatment With an Appropriate Second-line Therapy. — 178 Participants

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: Cerebral Metabolic Rate of Oxygen (CMRO2) — 8.17 micro-mol/100g/min

Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…

Primary: Number of Participants With Serious Adverse Drug Reactions (SADRs) — 1; 14 Participants

Primary: Annualized Relapse Rate (ARR) — 0.02 relapses per year

Primary: FF-VEP Latency of the Affected Eye as Compared to the Baseline of the Fellow Eye at 2 Years (+ up to 12 Months) After the Last Study Visit Assessment (Week 32) in RENEW…

Primary: Annualized Confirmed Relapse Rate — 0.202; 0.290 relapses per year — p=0.0003

Primary: Mean Number of New Inflammatory MRI Lesions Per Monthly Scans — 0.4; 1.7 New Lesions — p=0.87

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability

Primary: QTcB Change — 416.50; 416.41; 418.39; 423.27 ms

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Change From Screening in Selective Reminding Test - Long-Term Storage (SRT-LTS) Raw Score — 6.32; 4.46 raw score — p=0.4940

Primary: Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) Measured at Day 30 After the Mother's First…

Primary: Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio…

Primary: Change From Baseline in Patient-reported Treatment Satisfaction — 19.57; 5.83 score on a scale

Primary: Modified Rankin Score (mRS) Between Favorable CIS Group Versus Poor CIS Group. — 22; 1; 23; 10 Participants

Primary: Number of Days Until First On-study Relapse — NA; 103 days — p=0.125